Soma Sengupta, MD, PhD, FRCP, University of Cincinnati, Cincinnati, OH, and Pier Paolo Claudio, MD, PhD, University of Mississippi, Jackson, MS, summarise a collaborative Phase III trial (NCT03632135) which assessed whether ChemoID assay-guided therapy improves the survival of patients with recurrent high-grade glioma (HGG). The ChemoID platform is a cancer stem cell (CSC) test that provides physicians with an actionable tool for determining the appropriate therapy. Essentially, the ChemoID platform promotes survival by selecting the therapy which eliminates the CSCs responsible for cancer reoccurrence, spread and resistance to treatment. The trial demonstrated that patients with recurrent HGG whose treatment was guided by the ChemoID platform had a median overall survival of 3.5 months longer than patients whose treatment was determined by physicians’ choice. Following the acceptance and publication of this research, this technology platform can be implemented in clinical pathology laboratories. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2022 in New Orleans, LA.
